Skip to main content

CEO Update: Enveric to Spin-off and Dividend Cannabinoid Pipeline to Shareholders

By May 11, 2022No Comments

Dr. Joseph Tucker, CEO of Enveric Biosciences, details the Company’s plan to spin-off its #cannabinoid clinical development pipeline assets to a wholly-owned subsidiary, Acanna Therapeutics Inc. Following the spin-off, the resulting stand-alone public companies will focus their resources on the R&D of each company’s respective pipelines.